# Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Study · id `cardio:ct-nct03409107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03409107](<https://clinicaltrials.gov/study/NCT03409107>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03409107

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 614 participants.

## Technical summary

Registry record NCT03409107. Randomized; double masking; primary purpose treatment. Start 2018-03-05 (actual); primary completion 2020-10-07 (actual). Results posted on 2021-11-03.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 614 participants (enrolled count; ClinicalTrials.gov record NCT03409107, source copy `cardio:ctgov-nct03409107-2024-04-02`, retrieved 2026-10-26)
- Started: 2018-03-05 (actual) (ClinicalTrials.gov record NCT03409107, source copy `cardio:ctgov-nct03409107-2024-04-02`, retrieved 2026-10-26)
- Primary completion: 2020-10-07 (actual) (ClinicalTrials.gov record NCT03409107, source copy `cardio:ctgov-nct03409107-2024-04-02`, retrieved 2026-10-26)
- Completion: 2020-10-07 (actual) (ClinicalTrials.gov record NCT03409107, source copy `cardio:ctgov-nct03409107-2024-04-02`, retrieved 2026-10-26)
- Results first posted: 2021-11-03 (ClinicalTrials.gov record NCT03409107, source copy `cardio:ctgov-nct03409107-2024-04-02`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Canada; France; Italy; Mexico; Poland; Romania; Russia; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT03409107, source copy `cardio:ctgov-nct03409107-2024-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03409107-2024-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
- Condition: Anaemia
- Intervention (Drug): Daprodustat (GSK1278863)
- Intervention (Drug): Placebo
- Intervention (Drug): Iron therapy
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: 6a168dc4ece9140f4d5100c5d7169a149ad65f1d8c19df6e06921008b23dd9dc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
